11 Results for "

STAT3-SH2 domain

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "STAT3-SH2 domain" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-129603
CAS No.: 2429877-30-3
Purity:  98.96%
Research Areas:  

Cancer

SI-109 is a potent STAT3 SH2 domain inhibitor (Ki=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC50=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader SD-36 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-150603
CAS No.: 2248552-86-3
Purity:  99.24%
Research Areas:  

Cancer

STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
loading...
    loading...
Cat. No.: HY-151577
CAS No.: 2816059-41-1
Purity:  98.58%
Target:  

STAT Apoptosis

Research Areas:  

Cancer

STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
loading...
    loading...
Cat. No.: HY-121725
CAS No.: 1809581-87-0
Purity:  ≥99.0%
Target:  

STAT

Research Areas:  

Cancer

MM-206, a STAT3 activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC50 of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines .
loading...
    loading...
Cat. No.: HY-N6651
CAS No.: 22550-15-8
Isocryptotanshinone is a dual STAT3 and PTP1B (IC50 = 56.1 μM) inhibitor. Isocryptotanshinone inhibits STAT3 by binding to the STAT3 SH2 domain to block phosphorylation and nuclear translocation [1][2]. Isocryptotanshinone exerts its anti-proliferative effect via the induction of cell cycle arrest, apoptosis, and pro-death autophagy, through the regulation of STAT3, AKT/mTOR and MAPK signaling pathways. Isocryptotanshinone suppresses the xenograft gastric cancer (GC) tumor growth in BALB/c nude mice. Isocryptotanshinone can be used for cancer research, such as lung cancer, breast cancer and GC .
loading...
    loading...
Cat. No.: HY-164445
CAS No.: 2591440-71-8
Research Areas:  

Cancer

STAT3-IN-32 is an orally active, selective STAT3 SH2 domain inhibitor with a Kd of 21.3 nM, showing selectivity over STAT1/5. STAT3-IN-32 binds to the STAT3 SH2 domain, blocks Tyr705 and Ser727 phosphorylation, abrogates nuclear transcription and mitochondrial oxidative phosphorylation functions. STAT3-IN-32 inhibits tumor growth in mouse pancreatic cancer xenograft models. STAT3-IN-32 can be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-184734
Target:  

STAT NF-κB

Research Areas:  

Cancer

STAT3/NF-κB-IN-2 is a dual STAT3/NF-κB inhibitor that exhibits antiproliferative, antimigratory and anti-invasive activities in cancer cells. STAT3/NF-κB-IN-2 inhibits the transcriptional activities of NF-κB and STAT3, binds to the STAT3-SH2 domain, and blocks STAT3 dimerization. STAT3/NF-κB-IN-2 can be used in studies related to triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-146728
CAS No.: 2499491-04-0
Target:  

STAT Apoptosis

Research Areas:  

Cancer

STAT3-IN-10 is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, induces cancer cells apoptosis .
loading...
    loading...
Cat. No.: HY-182380
CAS No.: 1632152-27-2
ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC50 of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-184419
Target:  

STAT Apoptosis

Research Areas:  

Cancer

YZZ-24 is a highly potent and selective STAT3 inhibitor featuring a Ki of 0.26 μM. YZZ-24 directly binds to STAT3 (STAT3 SH2 domain) and effectively inhibits STAT3 phosphorylation at tyrosine 705 (p-STAT3 Tyr705) and STAT3 phosphorylation at serine 727 (p-STAT3 Ser727), thereby blocking downstream oncogenic signaling and inducing apoptosis, while having minimal impact on upstream kinases. YZZ-24 can be used in colorectal cancer research .
loading...
    loading...
Cat. No.: HY-180245
STAT3-IN-51 is a STAT3 inhibitor that directly binds to the STAT3 SH2 domain. STAT3-IN-51 induces apoptosis, ferroptosis, and immunogenic cell death (ICD) to potentiate anti-tumor immunity. STAT3-IN-51 inhibits STAT3 activation (phosphorylation, p-STAT3) and its downstream signaling. STAT3-IN-51 induces ROS generation, decreases Bcl-2 expression, disruptes mitochondrial function, suppresses GPX4 activity, and promotes lipid peroxidation. STAT3-IN-51 can be used for the study of colorectal carcinoma, breast adenocarcinoma, non-small cell lung cancer (NSCLC) and Cisplatin (HY-17394)-resistant pulmonary adenocarcinoma .
loading...
    loading...
  • 1